Table 1 Baseline characteristics in patients with or without diabetes
| Â | No diabetes (NÂ =Â 544) | Diabetes (NÂ =Â 219) | p value |
|---|---|---|---|
Age (years) | 65.4 ± 9.7 | 66.4 ± 9.7 | 0.24 |
Male | 74.8% (407) | 63.9% (140) | 0.003 |
BMI (kg/m2) | 26.8 ± 4.5 | 28.6 ± 5.0 | <0.0001 |
Smoking (current or past) | 47.8% (260) | 47.0% (103) | 0.85 |
Hypertension | 67.5% (367) | 81.3% (178) | <0.0001 |
Dyslipidemia | 61.4% (334) | 79.5% (174) | <0.0001 |
Family history of CAD | 26.1% (142) | 22.4% (49) | 0.28 |
Renal dysfunction (eGFRÂ <Â 60Â ml/min) | 8.6% (47) | 12.3% (27) | 0.12 |
Prior MI | 24.1% (131) | 30.6% (67) | 0.06 |
Prior PCI | 14.0% (76) | 17.4% (38) | 0.24 |
Peripheral vascular disease | 3.7% (20) | 6.4% (14) | 0.10 |
Clinical presentation | Â | Â | 0.37 |
 Stable | 79.2% (431) | 76.3% (167) |  |
 ACS | 20.8% (113) | 23.7% (52) |  |
 Unstable Angina | 9.2% (50) | 15.5% (34) |  |
 NSTEMI | 10.7% (58) | 6.8% (15) |  |
 STEMI | 0.9% (5) | 1.4% (3) |  |
Coronary vessel | Â | Â | 0.86 |
 Left main | 3.1% (17) | 3.7% (8) |  |
 LAD | 60.7% (330) | 59.4% (130) |  |
 LCx | 17.5% (95) | 19.6% (43) |  |
 RCA | 18.8% (102) | 17.4% (38) |  |
Contrast medium | Â | Â | 0.03 |
 Iobitridol | 5.3% (29) | 5.0% (11) |  |
 Iodixanol | 24.3% (132) | 26.0% (57) |  |
 Iohexol | 15.8% (86) | 9.1% (20) |  |
 Iomeprol | 31.1% (169) | 26.5% (58) |  |
 Iopamidol | 1.3% (7) | 0.5% (1) |  |
 Iopromide | 7.9% (43) | 11.9% (26) |  |
 Ioversol | 8.5% (46) | 10.0% (22) |  |
 Ioxaglate | 5.9% (32) | 11.0% (24) |  |
Volume of IC contrast (ml) | 7.9 ± 1.5 | 7.7 ± 1.6 | 0.03 |
 5 | 2.0% (11) | 2.7% (6) |  |
 6–7 | 39.7% (216) | 49.3% (108) |  |
 8–9 | 30.1% (164) | 21.0% (46) |  |
 10 | 27.9% (152) | 26.9% (59) |  |
 12 | 0.2% (1) | 0% (0) |  |
Dose of IC adenosine* (μg) | 166.3 ± 46.1 | 171.2 ± 47.1 | 0.27 |
 <80 | 2.3% (9) | 1.3% (2) |  |
 80–90 | 7.1% (28) | 7.1% (11) |  |
 100–150 | 28.4% (112) | 29.0% (45) |  |
 160–200 | 48.5% (191) | 45.2% (70) |  |
 >200 | 13.7% (54) | 17.4% (27) |  |